J.P. Morgan Remains a Buy on Intra-Cellular Therapies (ITCI)
In a report released on January 27, Jessica Fye from J.P. Morgan maintained a Buy rating on Intra-Cellular Therapies (ITCI – Research Report), ...
J.P. Morgan Sticks to Their Buy Rating for Ascendis Pharma (ASND)
J.P. Morgan analyst Jessica Fye maintained a Buy rating on Ascendis Pharma (ASND – Research Report) today and set a price target of $167.00.
JPMorgan raises Ascendis Pharma target to $167, keeps Overweight
JPMorgan analyst Jessica Fye adjusted the price target for Ascendis Pharma (NASDAQ:ASND), a $7.74 billion biotech company, to $167.00, a slight increase from the previous $165.00, while reiterating ...
Hosted on MSN4mon
Halozyme cut to Neutral at J.P. Morgan on valuation
Shares of Halozyme Therapeutics (NASDAQ:HALO) trended lower on Thursday after J.P. Morgan downgraded the ... However, analyst Jessica Fye raised her price target on HALO to $57 from $52 per ...
Seeking Alpha16d
Vertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani Hosts 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Great. Good morning, everyone. Welcome. I'm Jess Fye, Biotech Analyst at J.P. Morgan. We're kicking off the 43rd Annual Healthcare Conference this morning, and I couldn't be more delighted to ...